About TomegaVax
TomegaVax is a Healthcare company based in Beaverton (United States) founded in 2011, and was acquired by Vir Biotechnology in January 2017. Developing cytomegalovirus-vector based vaccines for viral infections. The company was acqui-hired. TomegaVax offers products and services including Mobile Home Sales, Escrow Services, and Advertising Services. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines; 3 of its 3 listed competitors have raised funding.
Company details
TomegaVax is an immunotherapy company focussed on developing vaccines for viral infections. It has developed a vaccine technology which uses a cytomegalovirus (CMV) vector and provides continuous low-level antigen presentation to maintain an active T-cell-mediated immune shield. It currently has preclinical and clinical CMV-based vaccine programs for chronic and recurring viral infections including Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Hepatitis B Virus (HBV) and Herpes Simplex Virus (HSV). It also states that the vaccines can not only prophylactically protect against infection but also control existing infections. It claims that these CMV-based vaccines have also demonstrated pre-clinical efficacy in animal models of Tuberculosis (TB), Malaria, Ebola Virus and cancers including prostate cancer and melanoma.
- Headquarters Beaverton, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website tomegavax.com
- Social LinkedIn Facebook
- Acquired by Vir Biotechnology (Jan 2017)
- Latest Funding Round$1.98M (USD), Grant
Mar 2017
- InvestorsVir Biotechnology
& 1 more
- Acquired byVir Biotechnology
(Jan 2017)
Products & Services of TomegaVax
TomegaVax offers a comprehensive portfolio of products and services, including Mobile Home Sales, Escrow Services, and Advertising Services.
Facilitates buying and selling of mobile homes in Oregon areas
Provides in-house escrow for home transactions and lending
Covers ads for home listings and buyer outreach
Funding Insights of TomegaVax
- Total Rounds 7
- Last Round Grant — $1.98M
- First Round $2.97M
(Apr 2012)
- Investors Count 1
All 7 funding rounds of TomegaVax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in TomegaVax
TomegaVax has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Vir Biotechnology and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of therapeutics for the treatment of infectious diseases | 2017 | vir.bio | San Francisco, United States |
Investor details for TomegaVax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of TomegaVax
4 dated milestones of TomegaVax across 6 years, from founding to its latest funding, stage changes and deals.
- Founded TomegaVax is founded.
- Funding First funding round of $3.0M.
- Exit Acquired by Vir Biotechnology.
- Funding Latest funding round, Grant, of $2.0M.
Competitors of TomegaVax
TomegaVax has 3 listed competitors in our database, 3 of them funded. They include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering |
Detailed competitors of TomegaVax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as TomegaVax (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TomegaVax
TomegaVax was founded in 2011 and raised its 1st funding round 1 year after it was founded.
TomegaVax is headquartered in Beaverton, United States. It is registered at Beaverton, Oregon, United States.
TomegaVax is an immunotherapy company focussed on developing vaccines for viral infections. It has developed a vaccine technology which uses a cytomegalovirus (CMV) vector and provides continuous low-level antigen presentation to maintain an active T-cell-mediated immune shield. It currently has preclinical and clinical CMV-based vaccine programs for chronic and recurring viral infections including Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Hepatitis B Virus (HBV) and Herpes Simplex Virus (HSV). It also states that the vaccines can not only prophylactically protect against infection but also control existing infections. It claims that these CMV-based vaccines have also demonstrated pre-clinical efficacy in animal models of Tuberculosis (TB), Malaria, Ebola Virus and cancers including prostate cancer and melanoma.
TomegaVax's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
TomegaVax offers Mobile Home Sales, Escrow Services, and Advertising Services.
TomegaVax has 2 investors. Key investors include Vir Biotechnology, and HHS.
Yes. TomegaVax was acquired by Vir Biotechnology in January 2017.